Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
NCT ID: NCT05017142
Last Updated: 2024-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2020-04-14
2071-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Pediatric onset MS and other inflammatory brain diseases (IBrainDs) are severe diseases affecting children and adolescents in a period of essential brain development. This possibly leads to a variety of focal neurological deficits as well as early cognitive impairment. In turn, the cognitive impairment may impact school performance and vocational achievements.
Timely diagnosis and treatment initiation as well as individually tailored management are important for a favorable disease course. However, the diagnosis of the different IBrainDs can be challenging, especially in young children, since their first acute inflammation is often accompanied by unspecific symptoms common to all IBrainDs. A systematic assessment of similarities and differences between clinical signs, symptoms, and diagnostic workup of different IBrainDs will enable faster and more reliable diagnosis.
Furthermore, neither epidemiological data nor information on health care management and disease outcome of pediatric IBrainD patients exist in Switzerland. Therefore, a national registry is being established, which will allow a deeper understanding of pediatric IBrainD epidemiology, clinical presentation, and management. Ultimately, the registry will improve the care of children suffering from an IBrainD in Switzerland.
The Swiss-Ped-IBrainD Registry (title: "Swiss Pediatric Inflammatory Brain Disease Cohort Study", project number: 2019-00377) has been approved by the ethics committees of Bern, the Ethikkommission Nordwest- und Zentralschweiz (EKNZ), the Ethikkommission Ostschweiz (EKOS), and the ethics committees of Zürich, Lausanne, Geneva, and Bellinzona.
Objectives:
The registry pursues the following goals:
1. Gathering representative, population-based epidemiological data on pediatric IBrainD in Switzerland.
2. Monitoring treatment, clinical course, education, social aspects, and outcomes of pediatric IBrainD patients.
3. Providing a platform to facilitate research, national and international collaboration and exchange of knowledge between experts.
The registry thus addresses the increasing requests for medical trial participation and promotes the exchange with existing adult registries (e.g., Swiss MS Registry).
Inclusion/exclusion criteria:
All patients living and/or treated in Switzerland with an IBrainD specified in the following list diagnosed from 2005 onward and with a disease onset before the age of 18.
* Optic neuritis
* Transverse myelitis
* Acute disseminated encephalomyelitis
* Multiple sclerosis
* Neuromyelitis optica spectrum disorders
* Myelin oligodendrocyte glycoprotein antibody-associated disease
* Anti-NMDA-R associated autoimmune encephalitis
* Anti-GAD65 associated autoimmune encephalitis
* Anti-AMPAR-1/2 associated autoimmune encephalitis
* Anti-Lgi-1 associated autoimmune encephalitis
* Anti-CASPR-2 associated autoimmune encephalitis
* Anti-GABAR-1/2 associated autoimmune encephalitis
* Onconeuronal antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) associated autoimmune encephalitis
* Hashimoto encephalopathy
* CNS vasculitis
* CNS sarcoidosis
* CNS Lupus
* Rasmussen's encephalitis
Excluded are patients with:
1. Neurological symptoms due to infectious diseases of the CNS
2. Genetic/metabolic causes of central demyelinating diseases
3. Neurological symptoms due to Guillain-Barré-Syndrome
Registration of Patients and Collection of Medical Data:
Pediatricians, pediatric neurologists, neurologists, specialists in rehabilitation, and primary care physicians at the participating centers are responsible to identify children with the listed IBrainDs during regular medical consultations. Upon identification, treating physicians inform patients and their parents orally and in writing about the Swiss-Ped-IBrainD. Patients (and their legal representatives if applicable) who want to participate must give their informed consent. Once a patient consents to participate, their medical data will be entered in the registry.
The diagnostic workup and treatment of patients continue as usual and are independent from participation; no examination will be carried out specifically for the Swiss-Ped-IBrainD.
Medical data is collected through the following sources:
* Medical records and reports
* Oral/written information from treating physician
* Oral/written information from patient/family
* Routine statistics and other medical registries
* Questionnaires for patients and families The data collection focuses on diagnostic, follow-up, and relapse variables.
Routine data and linkages:
Communities; Federal Statistical Office (e.g. the birth register, cause of death statistics, hospital statistics)
Current status:
Since 2020, the investigators have included 128 people diagnosed with an IBrainD.
Funding:
* Schweizerische Multiple Sklerose Gesellschaft
* PedNet Bern
* SwissPedRegistry, University of Bern
* Roche Pharma (Switzerland) Ltd
* Novartis Pharma Schweiz AG
* Biogen
* Sanofi
* Anna Mueller Grocholski-Stiftung
* Gottfried und Julia Bangerter-Rhyner Stiftung
* Fondation Johanna Dürmüller-Bol
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient population
Children, adolescents and adults diagnosed with an IBrainD from 2005 onward and with disease onset before age 18, who are born, treated or living in Switzerland
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent by patients (and/or legal representative(s), if applicable)
* Optic Neuritis
* Transverse Myelitis
* Acute disseminated encephalomyelitis
* Multiple Sclerosis
* Neuromyelitis Optica Spectrum Disorders
* Myelin oligodendrocyte glycoprotein antibody-associated disease
* Anti-NMDA-R Encephalitis
* Anti-GAD65 Associated Autoimmune Encephalitis
* Anti-AMPAR-1/2 Associated Autoimmune Encephalitis
* Anti-Lgi-1 Associated Autoimmune Encephalitis
* Anti-CASPR-2 Associated Autoimmune Encephalitis
* Anti-GABAR-1/2 Associated Autoimmune Encephalitis
* Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis
* Hashimoto Encephalopathy
* CNS Vasculitis
* CNS Sarcoidosis
* CNS Lupus
* Rasmussen Encephalitis
Exclusion Criteria
* Genetic/metabolic causes of central demyelinating diseases
* Neurological symptoms due to Guillain-Barré-Syndrome
36 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Schweizerische Multiple Sklerose Gesellschaft
OTHER
Insel Gruppe AG, University Hospital Bern
OTHER
Novartis
INDUSTRY
Anna Mueller Grocholski-Stiftung
UNKNOWN
Gottfried und Julia Bangerter- Rhyner-Stiftung, Basel
OTHER
Biogen
INDUSTRY
Roche Pharma (Switzerland) Ltd
UNKNOWN
Fondation Johanna Dürmüller-Bol
UNKNOWN
Kantonsspital Aarau
OTHER
University Children's Hospital Basel
OTHER
Ente Ospedaliero Cantonale, Bellinzona
OTHER
Kantonsspital Graubünden
OTHER
University Hospital, Geneva
OTHER
Centre Hospitalier Universitaire Vaudois
OTHER
Ostschweizer Kinderspital
OTHER
Kantonsspital Winterthur KSW
OTHER
Sanofi
INDUSTRY
Hôpital Fribourgeois
OTHER
University Children's Hospital, Zurich
OTHER
Luzerner Kantonsspital
OTHER
University of Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sandra Bigi, PD MD
Role: PRINCIPAL_INVESTIGATOR
ISPM, University of Bern, Bern; Kinderspital Zentralschweiz, Luzern
Sandra Bigi, PD MD
Role: STUDY_DIRECTOR
ISPM, University of Bern, Bern Kinderspital Zentralschweiz, Luzern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kantonsspital Aarau
Aarau, Canton of Aargau, Switzerland
Children's Hospital of Eastern Switzerland
Sankt Gallen, Canton of St. Gallen, Switzerland
University Children's Hospital Lausanne (CHUV)
Lausanne, Canton of Vaud, Switzerland
Kantonsspital Winterthur
Winterthur, Canton of Zurich, Switzerland
Pediatric Institute of Southern Switzerland, Ospedale San Giovanni
Bellinzona, Canton Ticino, Switzerland
Kantonsspital Graubünden
Chur, Kanton Graubünden, Switzerland
University Children's Hospital Basel, UKBB
Basel, , Switzerland
University Children's Hospital, Inselspital Bern
Bern, , Switzerland
Institute of Social and Preventive Medicine, University of Bern
Bern, , Switzerland
Hôpital Fribourgeois - Freiburger Spital
Fribourg, , Switzerland
University Hospitals of Geneva (HUG)
Geneva, , Switzerland
Kinderspital Zentralschweiz
Lucerne, , Switzerland
University Children's Hospital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Esmeralda Nava, Dr. med.
Role: primary
Oliver Maier, Dr. med.
Role: primary
Ingrid Beck
Role: backup
Stéphane Darteyre
Role: primary
Florian Bauder, Dr. med.
Role: primary
Barbara Goeggel Simonetti, PD Dr. med.
Role: primary
Susi Strozzi, Dr. med.
Role: primary
Patricia Dill, Dr. med.
Role: primary
Gabriela Oesch Nemeth, Dr. med.
Role: primary
Lorena F Hulliger
Role: primary
Mary Kurian, Dr. med.
Role: primary
Stéphanie Garcia-Tarodo, Dr. med.
Role: primary
Sandra Bigi
Role: primary
Annette Hackenberg, Dr. med.
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Website of the registry
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-00377
Identifier Type: -
Identifier Source: org_study_id